PATH Vaccine Solutions donations received

This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of December 2019. See the about page for more details.

Table of contents

Basic donee information

ItemValue
Country

Donation amounts by donor and year for donee PATH Vaccine Solutions

Donor Total 2015 2014 2013 2012 2011 2010 2009 2007 2006
Bill and Melinda Gates Foundation (filter this donee) 516,126,092.52 25,434,316.00 58,208,008.52 75,179,045.00 91,504,282.00 22,108,845.00 30,988,572.00 29,995,200.00 88,750,000.00 93,957,824.00
Total 516,126,092.52 25,434,316.00 58,208,008.52 75,179,045.00 91,504,282.00 22,108,845.00 30,988,572.00 29,995,200.00 88,750,000.00 93,957,824.00

Full list of donations in reverse chronological order (44 donations)

DonorAmount (current USD)Donation dateCause areaURLInfluencerNotes
Bill and Melinda Gates Foundation4,999,738.002015-12-02Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to accelerate the development of vaccines against many of the world's most important infectious diseases through the application of controlled human infection models (CHIM); Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation2,799,108.002015-12-02Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop a controlled human infection model employing a standardized and stable Enterotoxigenic Escherichia coli (ETEC) strain expressing CS6 antigen to accelerate vaccine development for use in developing countries; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation11,946,434.002015-11-05Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to reduce the morbidity and mortality rates among infants and children in the developing world due to diarrheal disease by advancing the development of safe, affordable, and efficacious new vaccines to prevent the leading bacterial causes of diarrhea, ETE; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation2,999,845.002015-11-05Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to establish an international standard for both manufacturers and regulators of Sabin Inactivated Polio Vaccine as they proceed down the development pathway to licensure and WHO Pre-qualification; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation1,204,652.002015-10-27Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to convene developing country vaccine manufacturers for a series of meetings that will contribute to the accelerated development and introduction of safe, affordable, and accessible rotavirus vaccines for use in the public sector of high-burden developing; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation1,372,057.002015-10-26Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support activities of the phase IV trials, coordinating the complex lab support/assay related activities, and develop an product development plan for nOPV; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation22,546.652015-10-02Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to reduce the number of deaths and hospitalizations of infants due to pneumonia and invasive pneumococcal disease (IPD) in the developing world by advancing the development of safe, effective and affordable new vaccines against S. pneumoniae; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation-22,546.652015-10-02Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support a portfolio of pneumococcal vaccine projects; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation112,482.002015-05-06Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support the participation of key investigators at an international conference on new developments in the field of vaccines for enteric diseases that are of global public health significance; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation2,293,091.002014-11-20Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to advance the development and evaluation of the promising new dmLT adjuvant by ensuring an expanded supply of high-quality clinical-grade material for use in trials designed to further investigate its ability to improve the immunogenicity and protective; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation344,888.002014-11-18Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to explore development of a nimble and focused experimental medicine (EM) approach to vaccine research; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation-322,743.562014-10-27Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to examine the etiology of cases of diarrhea at one rotavirus vaccine clinical trial site in India in order to gather data that will help establish priorities for future enteric vaccine development; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation3,796,149.002014-10-24Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to advance early clinical development of the bovine-human reassortant rotavirus strains (BRV) candidate ultimately expanding the global rotavirus vaccine market to increase affordability and improve access; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation4,197,230.002014-09-12Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to advance the development of two vaccine components potentially useful for preventing diseases common in low-resource countries using a technology that should make them available in higher quantities and at lower costs; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation49,348,904.002014-09-04Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to reduce the morbidity and mortality rates among infants and children in the developing world due to diarrheal disease by advancing the development of safe, affordable, and efficacious new vaccines to prevent the leading bacterial causes of diarrhea, ETE; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation-3,261,753.002014-07-23Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to examine the etiology of cases of diarrhea at one rotavirus vaccine clinical trial site in India in order to gather data that will help establish priorities for future enteric vaccine development; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation399,927.002014-06-24Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support an assessment of the feasibility and resource requirements for developing a group B streptococcus vaccine; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation1,447,117.002014-05-01Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to accelerate the development of high-quality and low-cost polio vaccines needed in the peri- and post-eradication era; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation-34,800.922014-03-31Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- To support the Respiratory Syncytial Virus (RSV) Vaccine Forum and Live Attenuated Influenza Vaccine (LAIV) Clinical Data Review Meeting; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation3,661,753.002013-11-22Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to examine the etiology of cases of diarrhea at one rotavirus vaccine clinical trial site in India in order to gather data that will help establish priorities for future enteric vaccine development; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation29,689,896.002013-11-19Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to protect infants through RSV maternal immunization; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation2,500,000.002013-11-19Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to reduce morbidity and mortality among infants and children in the developing world due to influenza, both seasonal and pandemic, by advancing the development of safe, effective, and affordable new vaccines against influenza virus that are suitable for u; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation2,819,689.002013-10-30Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to assist developing-country vaccine manufacturers (DCVMs) in establishing effective auditing and compliance systems through on-site inspections, mentoring, and training activities; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation2,179,901.002013-10-30Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to provide technical assistance to the Vaccine Product Acceleration Network (V-PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and assess Chemistry,; Aid type: Contributions to specific-purpose programmes and funds managed by international organisations (multilateral, INGO). Affected regions: South of Sahara|Bilateral, unspecified.
Bill and Melinda Gates Foundation363,444.002013-10-30Global health/malariahttps://iatiregistry.org/publisher/bmgf-- to provide technical assistance to the Vaccine Product Acceleration Network (V-PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and assess Chemistry,; Aid type: Contributions to specific-purpose programmes and funds managed by international organisations (multilateral, INGO). Affected regions: South of Sahara|Bilateral, unspecified.
Bill and Melinda Gates Foundation8,000,000.002013-10-22Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop safe, effective, and affordable vaccines for introduction into the developing world; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation198,725.002013-09-24Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to assess the dengue vaccine development efforts underway at Chengdu Institute of Biological Products (CDIBP); Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation189,840.002013-06-07Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- To support the Respiratory Syncytial Virus (RSV) Vaccine Forum and Live Attenuated Influenza Vaccine (LAIV) Clinical Data Review Meeting; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation10,637,500.002013-04-04Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to advance clinical development of a late-stage rotavirus vaccine candidate by a developing-country manufacturer, ultimately increasing affordability and access to sustainable rotavirus vaccine introduction in low-resource settings; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation14,938,297.002013-02-11Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to accelerate the development of safe, affordable, and efficacious new vaccines to reduce the morbidity and mortality caused by ETEC and Shigella in infants and young children in the developing world; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation59,570,400.002012-11-08Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to reduce the number of deaths and hospitalizations of infants due to pneumonia and invasive pneumococcal disease (IPD) in the developing world by advancing the development of safe, effective and affordable new vaccines against S. pneumoniae; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation4,892,727.002012-10-31Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to advance clinical development of second-generation rotavirus vaccine candidates by developing-country manufacturers, increasing global competitiveness of the products and improving access to sustainable rotavirus vaccine introduction; Aid type: Project-type interventions. Affected countries: India.
Bill and Melinda Gates Foundation26,666,502.002012-06-29Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- To support efforts to develop a low-cost polysaccharide conjugate vaccine against Streptococcus pneumoniae to reduce childhood morbidity and mortality from lower respiratory infections in low-income regions.; Aid type: Project-type interventions. Affected countries: India.
Bill and Melinda Gates Foundation374,653.002012-06-15Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to assess the capacity of six China National Biotec Group institutes to meet World Health Organization requirements for priority vaccines, to improve their potential to provide safe, effective, and affordable vaccines; Aid type: Contributions to specific-purpose programmes and funds managed by international organisations (multilateral, INGO). Affected countries: China.
Bill and Melinda Gates Foundation1,408,325.002011-12-11Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to assess the capacity of six China National Biotec Group institutes to meet World Health Organization requirements for priority vaccines, to improve their potential to provide safe, effective, and affordable vaccines; Aid type: Contributions to specific-purpose programmes and funds managed by international organisations (multilateral, INGO). Affected countries: China.
Bill and Melinda Gates Foundation15,740,726.002011-11-11Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to reduce severe illness and death among infants and children by evaluating non-replicating rotavirus vaccine candidates as viable alternatives to oral, live attenuated rotavirus vaccines; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation4,959,794.002011-10-21Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to accelerate the development of high-quality and low-cost polio vaccines needed in the peri- and post-eradication era; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation29,999,216.002010-11-22Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to advance clinical development of a late-stage rotavirus vaccine candidate by a developing-country manufacturer, ultimately increasing affordability and access to sustainable rotavirus vaccine introduction in low-resource settings; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation989,356.002010-11-17Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support planning and preparations for bioprocess, formulation, and early clinical development of non-replicating rotavirus vaccines; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation29,995,200.002009-11-20Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to advance the development and introduction of promising new rotavirus vaccine candidates; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation38,750,000.002007-11-08Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support research and development of new influenza vaccines to address pandemic influenza; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation50,000,000.002007-09-19Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop Shigella and ETEC vaccines that induce potent, broadly reactive, and persistent immunity and are effective in preventing disease in populations most at risk, especially young children; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified; affected countries: Kenya|Cambodia|Viet nam.
Bill and Melinda Gates Foundation18,957,824.002006-11-15Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to accelerate the development of a safe, affordable and efficacious rotavirus vaccine for the developing world; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.
Bill and Melinda Gates Foundation75,000,000.002006-03-23Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support a portfolio of pneumococcal vaccine projects; Aid type: Project-type interventions. Affected regions: Bilateral, unspecified.